Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT04066296
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Lumbar Spinal Stenosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liposomal bupivacaine — DRUG
    Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.

Study Details

Evaluate the benefit of using liposomal bupivicaine in lumbar laminectomies in terms of length of stay, IV narcotic use, 30-day narcotic use, visual analog score (VAS) and 30-day readmissions

Key Dates

Start date
Sep 8, 2019
Status verified
Sep 2024
Primary completion
Dec 31, 2024
Completion
Jan 31, 2025

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Liposomal Bupivicaine
    Treatment with liposomal bupivicaine
  • Active Comparator: Standard Local Anesthestic
    Treatment with Standard Local Anesthestic

Primary Outcome Measure

Overall length of hospital stay from hospital admission to hospital discharge [ Time Frame: From date of hospital admission until date of hospital discharge, assessed up to 2 weeks. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado Anschutz Medical CampusAuroraColorado80045
Jen Maitlen, BSN
[email protected]
303-724-1995

Find similar trials in Aurora, CO

By research site
University of Colorado Anschutz Medical Campus· Aurora, CO

Related Studies